Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

CD5, MYC Status May Predict Outcomes in DLBCL

Publish date:: February 3, 2020

Key clinical point: Dual expression of CD5 and MYC protein predicted better outcomes than either protein alone, or both non-expressed.

Major finding: Dual expression was a significant independent predictor for overall survival (P less than .0001) and PFS (P less than .0001) in DLBCL.

Study details: A retrospective review of 210 patients with de novo diffuse large B-cell lymphoma at a single institution.

Disclosures: The work was supported by National Natural Science Foundation of China. The authors reported no disclosures.

Citation:

LU T-X et al. Experimental and Molecular Pathology 2020. Vol. 112. [Feb].

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in DLBCL

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,

Survey quantifies COVID-19’s impact on oncology,

Sarcopenia is a predictor of overall survival in DLBCL patients,

Mutation tied to central nervous system collapse in DLBCL,